NCT04500587View on ClinicalTrials.gov

Phase 1 First in Human Study of ZN-d5 as a Single Agent

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

December 12, 2023

Study Completion Date

December 12, 2023

Conditions
Acute Myeloid LeukemiaNon Hodgkin Lymphoma
Interventions
DRUG

ZN-d5

Oral agent; 25 mg or 100 mg formulation

Trial Locations (14)

Unknown

Site 2708, Darlinghurst

Site 2704, Liverpool

Site 2710, Kurralta Park

Site 2709, Hobart

Site 1202, Sofia

Site 1201, Varna

Site 3201, Zagreb

Site 2403, Gdansk

Site 2901, Pusan

Site 2903, Seoul

Site 3001, Barcelona

Site 3005, Bilbao

Site 3003, Valencia

Site 2001, Kiev

All Listed Sponsors
lead

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

INDUSTRY

NCT04500587 - Phase 1 First in Human Study of ZN-d5 as a Single Agent | Biotech Hunter | Biotech Hunter